{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-047560","form_type":"8-K","ticker":"ACRV","cik":"0001781174","company_name":"Acrivon Therapeutics, Inc.","filed_at":"2024-04-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.061056+00:00","generated_at":"2026-06-03T09:48:32.203535+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Acrivon reports 50% confirmed ORR with ACR-368 in OncoSignature-positive gynecological cancers; cash ~$234M","bullets":["Phase 2b: 50% confirmed ORR in OncoSignature-positive ovarian/endometrial (10 pts), 0% ORR in negative (16), p=0.0038.","Median duration of response not yet reached; all responders remain on treatment.","ACR-2316 dual WEE1/PKMYT1 inhibitor IND filing accelerated to Q3 2024; clinical trial expected Q4 2024.","Preliminary cash $110M at March 31; pro forma $234M after private placement, funding into H2 2026.","Initial prospective validation of AP3 platform ability to predict ACR-368 responders."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-047560","json":"https://secwatch.observer/filing/0000950170-24-047560.json","markdown":"https://secwatch.observer/filing/0000950170-24-047560.md","text":"https://secwatch.observer/filing/0000950170-24-047560.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1781174/000095017024047560/0000950170-24-047560-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1781174/000095017024047560/acrv-20240424.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T09:48:32.203535+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}